Increased Activity of ENaC in Proteinuric Kidney Transplant Recipients

University of Southern Denmark14 enrolled

Overview

The aim of this study is to determine if amiloride, a diuretic drug, is capable of increasing renal salt excretion, lowering blood pressure and inhibiting uPA in kidney transplant recipients with proteinuria compared to normoalbuminuric transplant patients.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Kidney Transplant; Complications

Interventions

Standardized sodium dietDIETARY_SUPPLEMENT

Dietary Supplement: Standardized salt diet 150 mmol NaCl per day given as three meals daily for 5 consecutive days.

Tbl amilorideDRUG

Drug: Amiloride Amiloride tablet 10 mg two times daily (morning and afternoon) for one day

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * One Group of kidney transplant recipients with ACR\< 30mg/g * One Group of kidney transplant recipients with ACR \>300mg/g Exclusion Criteria: * Treatment with amiloride, spironolactone, aldosterone- or analogs or tranexamsyre * Pregnancy * Clinically relevant organic or systemic disease including malignancy * eGFR or creatinin-clearance \< 30ml/min * hyperkalemia (s-potassium \> 5,0mmol/l)

Locations (1)

Odense University Hospital

Odense, Denmark

Outcomes

Primary Outcomes

24-hour urinary sodium excretion induced by amiloride

Time frame: Change from baseline urinary sodium (after 4 days of standadized sodium diet) excretion at 24 hours after amiloride administration

Secondary Outcomes

Office or 24h blood pressure measurements

Time frame: Change from baseline office blood pressure at day 4 of salt diet and at 24 hours after amiloride administration

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.